文献速递炎症性肠病

英夫利西单抗生物类似药二次转换对炎症性肠病控制与药物谷浓度无不良影响

An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
PubMed 文献 · Aliment Pharmacol Ther · 2021-07-05

结果显示首次和二次转换患者的CRP、临床疾病活动指数及英夫利西单抗中位谷浓度在转换早期和1年时均无显著变化,临床缓解比例亦无显著改变,首次与二次转换的无应答丢失时间无显著差异。

要点

  • 首次或二次转换至SB2后,英夫利西单抗谷浓度无显著变化
  • 转换后早期和1年时临床缓解率与基线相比无显著差异
  • 首次与二次转换者的无应答丢失时间无显著差异

核心结论

  • 从一种英夫利西单抗生物类似药转换为另一种,无论首次还是二次转换,对英夫利西单抗谷浓度及临床和生化疾病活动均无不良影响。

主要发现

  • 首次转换者英夫利西单抗中位谷浓度基线vs早期为5.7 vs 6.6 µg/mL(P=0.05),基线vs 1年为5.7 vs 5.7 µg/mL(P=0.37)。
  • 二次转换者英夫利西单抗中位谷浓度基线vs早期为4.3 vs 4.9 µg/mL(P=0.07),基线vs 1年为4.3 vs 4.7 µg/mL(P=0.06)。
  • 临床缓解比例在早期为92% vs 基线91%(P=0.75),1年为95% vs 基线91%(P=0.16)。
  • 首次与第二次转换者无应答丢失时间无显著差异(P=0.69)。
  • CRP和临床疾病活动评分在转换早期和1年时与基线相比均无显著变化。

临床怎么用

  • 对于稳定使用英夫利西单抗生物类似药的炎症性肠病患者,首次或二次转换至另一种生物类似药SB2未显示对疾病控制和药物谷浓度产生不良影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologics account for a significant cost in inflammatory bowel disease (IBD) management; however, switching from infliximab originator to its biosimilars has enabled cost saving without compromising disease control. The effects on IBD activity and infliximab trough levels of a second switch to another biosimilar are, however, uncertain. AIMS: To assess the effects on disease activity and infliximab trough levels associated with switching from infliximab biosimilar CT-P13 to another biosimilar SB2 and compare outcomes in those switching for the first and second time. METHODS: IBD patients on CT-P13, including some previously switched from originator, were prospectively followed during a switch to SB2. C-reactive protein (CRP), trough infliximab level and clinical disease activity indices were collected at baseline, Infusion 3 or 4 ('early' after switch), and 1 year. RESULTS: One hundred eighty-six patients (n = 99 second switch) on stable infliximab dosing underwent switching. Compared with baseline, there was no significant change in CRP, clinical disease activity scores or median trough infliximab level at the early time point among first-switch (baseline vs early: 5.7 vs 6.6 µg/mL, P = 0.05) and second-switch (4.3 vs 4.9 µg/mL, P = 0.07) patients nor at 1 year (median infliximab trough levels, baseline vs 1 year, in first-switch [5.7 vs 5.7 µg/mL, P = 0.37] and second-switch [4.3 vs 4.7 µg/mL, P = 0.06] patients). The proportion of patients in clinical remission did not significantly change at the early (92% vs 91% at baseline, P = 0.75) or 1 year (95% vs 91% at baseline, P = 0.16) time points. There was no significant difference in time to loss of response between patients switching for the first or second time (P = 0.69). CONCLUSIONS: Switching from one infliximab biosimilar to another had no adverse impact on infliximab trough levels, and clinical and biochemical disease activity, regardless of whether switching for the first or second time.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Luber RP, O'Neill R, Singh S, et al. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther. 2021. PMID: 34223654. doi:10.1111/apt.16497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。